"Police in India have arrested the owner of a pharmaceutical company that manufactures a cough syrup connected to the deaths of at least 17 children in the country. Ranganathan Govindan, who runs the Tamil Nadu-based Sresan Pharmaceuticals, was taken into custody by Madhya Padhya Pradesh state police in Chennai on Wednesday night. Madhya Pradesh's police had been looking for Ranganathan since at least 17 children under the age of 5 died over the last month after allegedly consuming Coldrif cough syrup made by his company."
"India cough syrup scare India's Health Ministry has said test samples of Coldrif contained diethylene glycol (DEG) a highly toxic industrial solvent. The cough syrup was banned after a test confirmed the presence of the chemical on October 2. A report by the Tamil Nadu Drugs Control Department shows that cough syrup was manufactured in unhygienic factory conditions. An initial investigation has revealed that aside from Madhya Pradesh, the cough syrup was also supplied to Odisha and Puducherry, according to Indian media reports."
"The World Health Organization (WHO) said on Wednesday said India had a "regulatory gap" in testing locally sold syrup medicines, Reuters news agency reported. "WHO expresses deep concern over these developments and emphasizes... the regulatory gap in DEG/EG screening for domestically marketed medicines in India," Reuters cited a spokesperson of the United Nations health agency as saying."
Police arrested Ranganathan Govindan, owner of Sresan Pharmaceuticals, in Chennai in connection with deaths linked to a cough syrup. At least 17 children under five allegedly died after consuming Coldrif, manufactured by Sresan. India's Health Ministry confirmed test samples contained diethylene glycol (DEG), a highly toxic industrial solvent, prompting a ban on the product on October 2. The Tamil Nadu Drugs Control Department found unhygienic manufacturing conditions. Coldrif was reportedly supplied to Madhya Pradesh, Odisha, and Puducherry. Tamil Nadu will pursue criminal action. Authorities also warned against Respifresh and RELIFE after similar DEG findings, and WHO flagged screening gaps.
Read at www.dw.com
Unable to calculate read time
Collection
[
|
...
]